Related Experiment Video
Updated: Jan 20, 2026

Simultaneous Measurement of Mitochondrial Calcium and Mitochondrial Membrane Potential in Live Cells by Fluorescent Microscopy
Published on: January 24, 2017
MIM1 induces COLO829 melanoma cell death through mitochondrial membrane breakdown, GSH depletion, and DNA damage
Michalina Respondek1, Artur Beberok1, Zuzanna Rzepka1
1Department of Pharmaceutical Chemistry, School of Pharmacy with the Division of Laboratory Medicine, Medical University of Silesia, Jagiellońska, 441-200, Sosnowiec, Poland.
Abstract:
Malignant melanoma is a high aggressive malignancy in humans and causes 60-80% of deaths from skin cancer. Defect in an intrinsic pathway of apoptosis via overexpression of Mcl-1 is responsible for malignant melanoma development and progression, and also for resistance to chemotherapeutic agents. MIM1 is a specific low molecular Mcl-1 protein inhibitor that is able to induce Mcl-1-dependent cancer cells death. Here, we examined the effect of MIM1 as well as MIM1 and dacarbazine (DTIC) mixture on cell viability, apoptosis, and cell cycle progression in COLO829 melanoma cells. Cell viability was performed by the WST-1 assay. Analysis of apoptosis as well as cell cycle progression was determined by fluorescence image cytometer NucleoCounter NC-3000. The obtained results demonstrated that the MIM1 exhibited high cytotoxicity against melanotic melanoma cells and induced mitochondrial membrane breakdown, GSH depletion, and DNA fragmentation. Additionally, MIM1 enhanced the proapoptotic effect of DTIC toward melanoma cells; furthermore, a mixture of these drugs caused cell cycle arrest at G2/M phase in COLO829 cells. Taken together, these data provide, for the first time, evidence that a low molecular weight Mcl-1 inhibitor-MIM1 may be a promising agent with antitumor and proapoptotic properties toward melanoma cells.
Insights
Malignant melanoma cells can be killed by MIM1, a new Mcl-1 inhibitor. MIM1 also boosts chemotherapy effectiveness, offering a promising new treatment for melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Malignant melanoma is an aggressive skin cancer responsible for most skin cancer deaths.
- Overexpression of Mcl-1, a key protein in apoptosis, drives melanoma development and chemoresistance.
- Mcl-1 inhibitors offer a potential therapeutic strategy for melanoma.
Purpose of the Study:
- To investigate the anti-cancer effects of MIM1, a novel Mcl-1 inhibitor, on melanoma cells.
- To evaluate the combined effects of MIM1 and dacarbazine (DTIC) on melanoma cell viability, apoptosis, and cell cycle progression.
Main Methods:
- COLO829 melanoma cells were treated with MIM1 and/or DTIC.
- Cell viability was assessed using the WST-1 assay.
- Apoptosis and cell cycle progression were analyzed using fluorescence image cytometry (NucleoCounter NC-3000).
Main Results:
- MIM1 demonstrated significant cytotoxicity against melanoma cells, inducing mitochondrial dysfunction, GSH depletion, and DNA fragmentation.
- MIM1 enhanced the proapoptotic effects of DTIC.
- A combination of MIM1 and DTIC induced G2/M phase cell cycle arrest in COLO829 cells.
Conclusions:
- MIM1 exhibits potent antitumor and proapoptotic properties against melanoma cells.
- MIM1 shows promise as a therapeutic agent for melanoma, particularly in combination with chemotherapy.
- This study provides the first evidence for the efficacy of MIM1 as an Mcl-1 inhibitor in melanoma treatment.
Related Concept Videos
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
The Inner Mitochondrial Membrane
Mitochondrial Membranes
Protein Transport into the Inner Mitochondrial Membrane
Transport of mitochondrial precursors across the TIM23 channel is driven by...
Animal Mitochondrial Genetics

